Phase 3 trial in China successfully confirms ACARIZAX® safety and efficacy in patients with house dust mite allergy
Inside Information
Read the full story on GlobeNewswire → Opens the original article on www.globenewswire.comSummary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.